Humasis Co. Ltd (205470) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Humasis Co. Ltd (205470) has a cash flow conversion efficiency ratio of 0.036x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩8.98 Billion ≈ $6.08 Million USD) by net assets (₩248.94 Billion ≈ $168.71 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Humasis Co. Ltd (205470) net asset quality to measure how much of total assets are equity-financed.
Humasis Co. Ltd - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Humasis Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check 205470 cash to earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Humasis Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Humasis Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Caisse Regionale De Credit Agricole Mutuel Sud Rhone Alpes
PA:CRSU
|
0.030x |
|
Doktas Dokumculuk Ticaret ve Sanayi AS
IS:DOKTA
|
0.066x |
|
VIROMED MEDICAL NA O.N.
XETRA:VME
|
N/A |
|
Formuepleje Limittellus
CO:FPILIM
|
N/A |
|
Alcatel Lucent Teletas Telekomunikasyon AS
IS:ALCTL
|
-0.122x |
|
Ram Essential Services Property Fund
AU:REP
|
0.018x |
|
POLARIS RENEWABLE ENERGY
F:N4T
|
N/A |
|
Vizsla Royalties Corp.
V:VROY
|
-0.007x |
Annual Cash Flow Conversion Efficiency for Humasis Co. Ltd (2016–2024)
The table below shows the annual cash flow conversion efficiency of Humasis Co. Ltd from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see Humasis Co. Ltd market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ₩229.26 Billion ≈ $155.37 Million |
₩30.37 Billion ≈ $20.58 Million |
0.132x | +168.60% |
| 2023-12-31 | ₩287.33 Billion ≈ $194.72 Million |
₩-55.48 Billion ≈ $-37.60 Million |
-0.193x | -133.05% |
| 2022-12-31 | ₩346.73 Billion ≈ $234.98 Million |
₩202.60 Billion ≈ $137.30 Million |
0.584x | -42.43% |
| 2021-12-31 | ₩202.01 Billion ≈ $136.90 Million |
₩205.02 Billion ≈ $138.94 Million |
1.015x | +246.69% |
| 2020-12-31 | ₩48.84 Billion ≈ $33.10 Million |
₩14.30 Billion ≈ $9.69 Million |
0.293x | +472.45% |
| 2019-12-31 | ₩15.24 Billion ≈ $10.33 Million |
₩779.58 Million ≈ $528.31K |
0.051x | +210.38% |
| 2018-12-31 | ₩16.13 Billion ≈ $10.93 Million |
₩-747.08 Million ≈ $-506.29K |
-0.046x | +75.66% |
| 2017-12-31 | ₩15.60 Billion ≈ $10.57 Million |
₩-2.97 Billion ≈ $-2.01 Million |
-0.190x | -1468.41% |
| 2016-12-31 | ₩10.86 Billion ≈ $7.36 Million |
₩151.11 Million ≈ $102.40K |
0.014x | -- |
About Humasis Co. Ltd
Humasis Co. Ltd. manufactures and sells pharmaceuticals and medical devices in South Korea and internationally. It offers immunodiagnostic kits, such as quantitative and qualitative tests, cardiac and cancer markers, infectious diseases, hormones, and women's health. The company also provides bio-material products, such as COVID-19 nucleocapsid protein, human immunodeficiency virus surface protei… Read more